Cardlytics, Inc. (CDLX) intrinsic value & 10-year financials
Cardlytics, Inc. (CDLX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 7.3% a year to $212.3M, with an average return on invested capital of -13.3%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.03
- Market cap
- $107.8M
- Revenue (FY2025)
- $212.3M
- Revenue growth (10-yr CAGR)
- 7.3%
- ROIC (10-yr avg)
- -13.3%
- Free cash flow (FY2025)
- $8.8M
CDLX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $212.3M | -$103.5M | -$1.95 | $8.8M | -48.0% | -54.8% |
| FY2024 | $255.6M | -$189.3M | -$3.91 | -$10.4M | -76.5% | -75.4% |
| FY2023 | $285.4M | -$134.7M | -$3.69 | -$852.0K | -47.5% | -44.0% |
| FY2022 | $277.2M | -$465.3M | -$13.92 | -$55.1M | -165.2% | -94.7% |
| FY2021 | $258.8M | -$128.6M | — | -$41.6M | -47.4% | -47.8% |
| FY2020 | $186.9M | -$55.4M | — | -$13.0M | -28.9% | 110.9% |
| FY2019 | $210.4M | -$17.1M | — | $3.2M | -8.2% | -35.4% |
| FY2018 | $150.7M | -$53.0M | — | -$24.9M | -27.2% | 71.9% |
| FY2017 | $130.4M | -$19.6M | — | -$23.3M | -13.1% | 9.9% |
| FY2016 | $112.8M | -$75.7M | — | -$34.3M | -49.8% | 25.9% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Cardlytics, Inc. has demonstrated mature, steady growth, with revenue compounding at 7.3% annually over the past decade.
Cardlytics, Inc. has historically struggled to out-earn its cost of capital, averaging just -17.7% ROIC.
Cardlytics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Cardlytics, Inc. is modeled at 7.3% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-38.80 per share.